DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Japanese Bridging Study Conducted in the United States

Phase 1

Withdrawn

Conditions: Hepatitis C Virus

Interventions: Drug: BMS-791325
Drug: Placebo

First Posted Date: 2009-07-28

Last Posted Date: 2013-07-18

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT00947245

Locations: 🇺🇸
Local Institution, Cypress, California, United States

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Phase 1

Completed

Conditions: Renal Cell Carcinoma
Non-hodgkin's Lymphoma

Interventions: Biological: MDX-1203

First Posted Date: 2009-07-23

Last Posted Date: 2013-05-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 46

Registration Number: NCT00944905

Locations: 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸
The University of Michigan Health System, Ann Arbor, Michigan, United States

and more 2 locations

Ex Vivo Human Thrombosis Chamber Study

Phase 1

Completed

Conditions: Cardiovascular Disease

Interventions: Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2009-07-09

Last Posted Date: 2011-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT00935506

Locations: 🇺🇸
Mds Pharma Services, Neptune, New Jersey, United States

Abatacept Versus Adalimumab Head-to-Head

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Abatacept
Drug: Adalimumab

First Posted Date: 2009-06-30

Last Posted Date: 2014-02-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 869

Registration Number: NCT00929864

Locations: 🇺🇸
Laureate Clinical Research Group, Atlanta, Georgia, United States
🇺🇸
Mountain State Clinical Research, Clarksburg, West Virginia, United States
🇺🇸
Arthritis And Rheumatic Disease Specialties, Aventura, Florida, United States

and more 61 locations

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: BMS-833923
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2009-06-25

Last Posted Date: 2013-06-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5

Registration Number: NCT00927875

Locations: 🇮🇪
Local Institution, Dublin, Ireland
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

Long-term Data Collection for Subjects in MDX-010 Studies

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2009-06-25

Last Posted Date: 2010-04-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 160

Registration Number: NCT00928031

Locations: 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸
Arizona Cancer Center, Tuscon, Arizona, United States
🇺🇸
Pacific Shores Medical Group, Long Beach, California, United States

and more 8 locations

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Phase 1

Completed

Conditions: Advanced Melanoma

Interventions: Biological: Ipilimumab

First Posted Date: 2009-06-15

Last Posted Date: 2014-06-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 99

Registration Number: NCT00920907

Locations: 🇺🇸
California Pacific Medical Center, San Francisco, California, United States
🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States

and more 4 locations

Safety, Pharmacokinetics and Pharmacodynamics Study to Evaluate BMS-830216 in Obese Subjects

Phase 1

Completed

Conditions: Obesity

Interventions: Drug: BMS-830216
Drug: Placebo

First Posted Date: 2009-05-28

Last Posted Date: 2015-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 113

Registration Number: NCT00909766

Locations: 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States

A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Phase 1

Completed

Conditions: Stomach Neoplasms
Esophageal Neoplasms

Interventions: Drug: BMS-833923
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2009-05-28

Last Posted Date: 2013-06-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 39

Registration Number: NCT00909402

Locations: 🇳🇱
Local Institution, Amsterdam, Netherlands
🇺🇸
City Of Hope National Medical Center, Duarte, California, United States
🇺🇸
Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 1 locations

Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Phase 3

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Brivanib
Other: Brivanib Placebo
Procedure: TACE Therapy

First Posted Date: 2009-05-27

Last Posted Date: 2019-12-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 734

Registration Number: NCT00908752

Locations: 🇺🇸
The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Sharp Clinical Oncology Research, San Diego, California, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy